All In Biotech

NDA 209355 · Bausch

Bryhali

Halobetasol Propionate · Topical

Last checked: Nov 20, 2026Latest source record: Nov 6, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 6, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

28

6 Phase 3, 0 recruiting

FAERS reports

978

287 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 1, 2020.

BRYHALI ® (halobetasol propionate) lotion, 0.01% is indicated for the topical treatment of plaque psoriasis in adults. BRYHALI lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in adults. ( 1 )

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BRYHALI · HALOBETASOL PROPIONATE 0.01% · LOTION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Halobetasol Propionate" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective199
  • psoriasis139
  • pruritus99
  • product use in unapproved indication81
  • rash70
  • dermatitis atopic58
  • pain53
  • arthralgia51
  • dry skin51
  • skin exfoliation47
  • fatigue45
  • product dose omission issue45

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20053
20062
20103
20116
20129
201314
201411
201526
201636
201727
201831
201953
202070
202184
2022146
2023235
202482
202571
202669

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bryhali (Halobetasol Propionate)

2024 spending

$101K

Beneficiaries

136

228 claims

Per beneficiary

$739

$5.24 per unit

View as table
YearSpending
2020$353,712
2021$238,201
2022$198,289
2023$141,568
2024$100,541

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.